In this study, our aim was to assess the therapeutic potential of combining empagliflozin, a SGLT2 inhibitor, with calorie restriction and bone marrow (BM)-MSC therapy compared to BAT and WAT transplantation in a murine pre-clinical model of type 2 DM (T2DM), obesity, and DKD. This evidence concerns the gene SLC5A2 and obesity disorder.